Saxagliptin Triple Oral Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 257 participants.
Also called NCT01128153
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 257 participants
- Sponsor
- Registry
-
NCT01128153
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Australia, Canada, India, South Korea, Thailand, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01128153. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2012-08-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Saxagliptin Triple Oral Therapy
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Saxagliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct01128153- Content hash
95e717e37f884db6ebe3200fc5d0fbc9d2ddb393950bb2c3ba29e950f51d10f2